Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 77
GLP-1 drugs and mental health: a 2026 study
A June 2026 cohort study found lower rates of anxiety and depression in adults on tirzepatide or semaglutide vs other weight-loss drugs, and what that means.
Tirzepatide and steatotic liver disease
A 2026 real-world study finds tirzepatide cut major liver complications and mortality in adults with steatotic liver disease and cardiometabolic dysfunction.
Tirzepatide vial crystals: what they mean
A tirzepatide vial with residue or cloudiness fails the licensed product's visual standard. Here is what the physical changes signal and what to do.
GLP-1/GIPR/FGF21 peptibody in DIO mice
A preclinical peptibody hitting GLP-1, GIPR, and FGF21 reduced body weight and improved metabolic markers in obese mice. Human translation is unknown.
Ipamorelin history: discovery to today
Ipamorelin was first characterised at Novo Nordisk in 1998. Here is the research timeline and why no approved medicine followed.
How ipamorelin works: mechanism explained
Ipamorelin binds the GHS-R1a receptor to trigger a selective growth-hormone pulse without raising cortisol or prolactin.
Ipamorelin side effects: what trials report
Ipamorelin has no approved label and no official adverse-event profile. Here is what the one human clinical trial and early pharmacokinetic work found.
Is ipamorelin banned in sport? WADA status
Ipamorelin is prohibited in and out of competition under WADA section S2. Here is why S2 applies and what competing athletes need to know.
Is tesamorelin legal? US, EU, and UK status
Tesamorelin is FDA-approved in the US for HIV-associated lipodystrophy. No EU or UK marketing authorisation exists.
Is tirzepatide legal? EU, UK and US status
Tirzepatide is prescription-only in the US, EU, and UK. Here is what legal access looks like across each jurisdiction.
GLP-1 drugs and the 2025 US health bill
US health spending hit $5.7 trillion in 2025, up 7.3%, and GLP-1 drugs like semaglutide and tirzepatide are a named driver. Here is what the numbers say.
One blood test, 54 peptide doping agents
A 2026 Ghent University method screens 54 peptide and non-peptide doping agents, including TB-500 and BPC-157, in dried and liquid blood in a single fast run.